AnalystsPaul JengPaul Jeng's Stock Forecasts
AnalystsPaul Jeng
Sectors:
Industries:
Analyst Ranking
Bottom 20%
#4325 out of 5334 analysts
Average Return
-2.15%
Win Rate
45%5 out of 11
Risk vs Reward
Poor
Good
Paul Jeng's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Adagene IncADAG | +68.42% | $1.90 | $3.20 | 2025-11-24 - 2026-07-24 | Strong Buy |
Immatics NvIMTX | +37.37% | $6.61 | $9.08 | 2025-09-18 - 2026-07-24 | Strong Buy |
Ideaya Biosciences IncIDYA | +35.01% | $26.22 | $35.40 | 2025-09-18 - 2026-07-24 | Strong Buy |
Ideaya Biosciences IncIDYA | +14.49% | $30.92 | $35.40 | 2026-02-18 - 2026-07-24 | Strong Buy |
Ideaya Biosciences IncIDYA | +9.43% | $32.35 | $35.40 | 2026-04-14 - 2026-07-24 | Strong Buy |
Paul Jeng Analyst Color
Get additional color on Paul Jeng's coverage of popular stocks
Paul Jeng's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Corbus Pharmaceuticals Holdings IncCRBP | 2 | Strong Buy | $45.00 | +390.73% | Reiterates | 2 months ago |
Ideaya Biosciences IncIDYA | 3 | Strong Buy | $54.00 | +52.54% | Maintains | 3 months ago |
Adagene IncADAG | 2 | Strong Buy | $10.00 | +212.50% | Maintains | 4 months ago |
Context Therapeutics IncCNTX | 2 | Strong Buy | $5.00 | +714.33% | Reiterates | 4 months ago |
Immatics NvIMTX | 2 | Strong Buy | $19.00 | +109.25% | Maintains | 8 months ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.